Switch theme
Sign up to access all valuation multiples
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. Its growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
2012
209
LTM Revenue $76.2M
LTM EBITDA -$31.0M
$54.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TELA Bio has a last 12-month revenue (LTM) of $76.2M and a last 12-month EBITDA of -$31.0M.
In the most recent fiscal year, TELA Bio achieved revenue of $69.3M and an EBITDA of -$31.7M.
TELA Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TELA Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $76.2M | XXX | $69.3M | XXX | XXX | XXX |
| Gross Profit | $51.6M | XXX | $46.5M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | -$31.0M | XXX | -$31.7M | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -46% | XXX | XXX | XXX |
| EBIT | -$32.5M | XXX | -$41.7M | XXX | XXX | XXX |
| EBIT Margin | -43% | XXX | -60% | XXX | XXX | XXX |
| Net Profit | -$36.2M | XXX | -$37.8M | XXX | XXX | XXX |
| Net Margin | -47% | XXX | -55% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TELA Bio's stock price is $1.
TELA Bio has current market cap of $55.0M, and EV of $54.0M.
See TELA Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.0M | $55.0M | XXX | XXX | XXX | XXX | $-1.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TELA Bio has market cap of $55.0M and EV of $54.0M.
TELA Bio's trades at 0.8x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate TELA Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TELA Bio has a P/E ratio of -1.5x.
See valuation multiples for TELA Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55.0M | XXX | $55.0M | XXX | XXX | XXX |
| EV (current) | $54.0M | XXX | $54.0M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTELA Bio's last 12 month revenue growth is 23%
TELA Bio's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
TELA Bio's rule of 40 is -46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TELA Bio's rule of X is 18% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TELA Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -46% | XXX | XXX | XXX |
| EBITDA Growth | -43% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -46% | XXX | -22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 93% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 127% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TELA Bio acquired XXX companies to date.
Last acquisition by TELA Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . TELA Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TELA Bio founded? | TELA Bio was founded in 2012. |
| Where is TELA Bio headquartered? | TELA Bio is headquartered in United States of America. |
| How many employees does TELA Bio have? | As of today, TELA Bio has 209 employees. |
| Who is the CEO of TELA Bio? | TELA Bio's CEO is Mr. Anthony Koblish. |
| Is TELA Bio publicy listed? | Yes, TELA Bio is a public company listed on NAS. |
| What is the stock symbol of TELA Bio? | TELA Bio trades under TELA ticker. |
| When did TELA Bio go public? | TELA Bio went public in 2019. |
| Who are competitors of TELA Bio? | Similar companies to TELA Bio include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of TELA Bio? | TELA Bio's current market cap is $55.0M |
| What is the current revenue of TELA Bio? | TELA Bio's last 12 months revenue is $76.2M. |
| What is the current revenue growth of TELA Bio? | TELA Bio revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of TELA Bio? | Current revenue multiple of TELA Bio is 0.7x. |
| Is TELA Bio profitable? | Yes, TELA Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TELA Bio? | TELA Bio's last 12 months EBITDA is -$31.0M. |
| What is TELA Bio's EBITDA margin? | TELA Bio's last 12 months EBITDA margin is -41%. |
| What is the current EV/EBITDA multiple of TELA Bio? | Current EBITDA multiple of TELA Bio is -1.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
